Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVEC: Nivolumab Induction in MMRd Endometrial Cancer
NCT05795244Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2023
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in endometrial cancer (EC), sponsored by Yonsei University. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05795244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795244.